- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple myeloma
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 1856KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 656KB)
Elotuzumab – November 2020
Elotuzumab: Powder for I.V. infusion 300 mg, Powder for I.V. infusion 400 mg; Empliciti®
Last updated
19 March 2021